1. Recommendations for the management of patients with homozygous familial hypercholesterolaemia: Overview of a new European Atherosclerosis Society consensus statement 
Eric Bruckert 
Atherosclerosis Supplements 
Volume 15, Issue 2, Pages (September 2014)
DOI: /j.atherosclerosissup
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1
Number of publications on homozygous familial hypercholesterolaemia identified using PubMed in March 2013, shown by year from 2007 to 2012.
Atherosclerosis Supplements  , 26-32DOI: ( /j.atherosclerosissup )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2 The heterogeneity of homozygous familial hypercholesterolaemia.
Atherosclerosis Supplements  , 26-32DOI: ( /j.atherosclerosissup )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

4. Fig. 3
Reduction in low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolaemia receiving statin therapy alone or in combination with ezetimibe (EZE) [11]. †All patients were receiving statin 40 mg at baseline and prior to switch; *p = 0.02 versus statin only 80 mg; **p < 0.01 versus statin only 80 mg.
Atherosclerosis Supplements  , 26-32DOI: ( /j.atherosclerosissup )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

5. Fig. 4
Estimation of low-density lipoprotein cholesterol (LDL-C) levels achieved upon treatment with current therapies in patients with homozygous familial hypercholesterolaemia, according to the severity of the disease.
Atherosclerosis Supplements  , 26-32DOI: ( /j.atherosclerosissup )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions